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Abstract. Rocky Mountain spotted fever (RMSF) is an emerging public health issue on some American Indian reser-
vations in Arizona. RMSF causes an acute febrile illness that, if untreated, can cause severe illness, permanent sequelae
requiring lifelong medical support, and death. We describe costs associated with medical care, loss of productivity, and
death among cases of RMSF on two American Indian reservations (estimated population 20,000) between 2002 and
2011. Acute medical costs totaled more than $1.3 million. This study further estimated $181,100 in acute productivity
lost due to illness, and $11.6 million in lifetime productivity lost from premature death. Aggregate costs of RMSF cases
in Arizona 2002–2011 amounted to $13.2 million. We believe this to be a significant underestimate of the cost of the
epidemic, but it underlines the severity of the disease and need for a more comprehensive study.
Rocky Mountain spotted fever (RMSF) is a tick-borne
rickettsial disease caused by the bacterium Rickettsia rickettsii.
RMSF has been endemic in parts of the United States for well
over a century, but emerged on tribal lands of Arizona in 2003.1
From 2000 to 2007, it was demonstrated that American Indians
were experiencing a disproportionate burden of disease
compared with other race groups (four times the burden of
RMSF than whites).2
RMSF is known to cause an acute febrile illness potentially
resulting in severe sequelae or death. Initial clinical presenta-
tion can vary widely and symptoms are often nonspecific in
nature, making timely diagnosis difficult.3 When treatment is
delayed past day 5 of symptoms, severe sequelae, such as
neurological deficits or damage to internal organs, may
occur.4 Such sequelae can cause irreparable damage requir-
ing long-term hospital care and lifelong medical support. The
case fatality rate of RMSF in Arizona is markedly higher
than is observed elsewhere in the United States, averaging
7% of reported cases compared with < 1% nationally.2,5 Dis-
ease severity, long-term or permanent sequelae, and the poten-
tial for fatal outcome all contribute to the disease burden in
this region. The costs of this epidemic are difficult to calcu-
late, and must take into account not only acute care medical
expenses but also potential loss of productivity due to illness
or death.
A retrospective chart review was performed within two
American Indian communities at the center of this epidemic.
Medical charts for cases of RMSF diagnosed between June 1,
2002 and September 30, 2011 from Indian Health Service
(IHS) facilities and referral hospitals were reviewed by Regan
and others4 and Traeger and others.3 Case definitions used in
this analysis follow those initiated by the original chart
review.3,4 Table 1 gives selected characteristics of the case
population from the analysis performed by Regan and
others, as well as events at discharge.4
Costs associated with RMSF cases in these localities were
considered for 2002–2011. To assess the financial burden of
RMSF within affected communities, direct medical costs
associated with acute medical care and indirect costs associ-
ated with productivity lost due to illness and premature death
were calculated. All estimates were adjusted to 2011 dollar
values based on inflation rates.6
The chart review captured visits to IHS and non-IHS facili-
ties relating to acute disease management of diagnosed RMSF
infections. We enumerated each visit type (classifying them
as outpatient, emergency room (ER), inpatient/general admis-
sion, and inpatient/intensive care unit (ICU) admission). IHS
reimbursement rates are standardized costs used by the Center
for Medicaid Services to compensate IHS and tribal facili-
ties for Medicaid reimbursable services. Rates are based on
encounters, not specific services, and are considered “all-
inclusive.” Daily rates were used for inpatient visits (includ-
ing general hospital admission and ICU) and outpatient visits
(including ER and clinic and hospital outpatient) were counted
by encounter according to 2011 values.7 Inpatient days were
calculated using dates of admission and discharge. The com-
munities included in this study have limited on-site hospital
facilities and treatment capacity for severe cases, and must
transfer patients requiring intensive care. As such, cost of trans-
fer was also included in the estimation of acute medical costs.
Costs of air evacuations were negotiated locally and were esti-
mated at $1,500 per one-way trip (Traeger, M. S., personal
communication). Estimated value is consistent with air ambu-
lance fee-for-service charges reported by the Arizona Health
Care Cost Containment System (AHCCCS).8 For each patient,
the cost per visit was multiplied by the number of each respec-
tive visit type and added to the cost of transfer, if applicable.
The sum of these values is the estimate of acute medical costs
associated with RMSF in these two communities.
Costs associated with acute productivity lost due to disease
were based on estimates calculated by Grosse and others.9
The hourly rates of compensation used in the calculation of
daily, annual, and lifetime production in the Grosse and
others’ paper were based on national averages from the
Bureau of Labor and Statistics.10 National averages for
annual income are nearly twice as large as annual income for
the population in question, so a correction factor was applied
to the Grosse estimates to compensate for this difference
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and more precisely address local rates.10 The correction fac-
tor used gender-specific average income of American Indians
living in Arizona over gender-specific annual income for all
ages provided in the Grosse paper.9,10 It was assumed, varia-
tions in compensation by age and time spent in market and
household tasks did not differ between the study population
and the national average.
The number of days of productivity lost due to RMSF was
calculated by combining the number of days spent at each
health-care visit (this would include 1 day for outpatient or
ER visits and any inpatient days) plus 4 days for recovery
regardless of disease severity. Age and gender-specific daily
production values from Grosse and others,9 which were
adjusted for inflation and local annual income, were then
applied to the number of productivity days lost. For cases
involving children (persons under 15 years of age) lost pro-
ductivity for a 30-year-old female was used to serve as the
productivity lost by a caregiver.
To calculate potential earnings lost from a premature
death due to disease, we used the age- and gender-specific
lifetime productivity estimates from Grosse and others, and
adjusted them based on local annual income, as was done for
acute productivity lost.9 Using the age at death for each of
the fatal cases, we applied the population-adjusted age and
gender-specific lifetime production lost at a 3% discount rate.
Two hundred and five cases were identified in the medical
chart review according to the probable and confirmed case
definitions. Twenty-nine people were admitted to the ICU and
15 people died. Table 2 shows the results for acute medical
costs for all 205 cases. Summary of daily production value lost
due to acute disease was $181,100 (95% confidence interval
[CI]: $175,954, $186,240). On average, 1.5 (range 0–8) days
were lost for outpatient visits (clinic and ER visits), 6.9 (range
0–55) days were lost for days spent in the hospital, and 4 days
were added for the recovery of every patient. Lifetime pro-
ductivity lost due to premature death from RMSF was esti-
mated at $11,631,998 (95% CI: $11,304,814, $11,959,182).
Aggregate economic costs of RMSF 2002–2011 surmounted
to $13,184,968 (95% CI: $12,852,638, $13,517,292), as shown
in Table 3.
The recent emergence of RMSF in Arizona has left devas-
tation in its wake. This severe, but relatively isolated outbreak
has cost millions of dollars in medical fees and economic pro-
ductivity lost. Lifetime productivity loss accounts for 88% of
the overall cost of disease in this evaluation. The average life-
time productivity lost per fatal case of RMSF ($775,467 per
death) is far greater than similar estimates for pneumococcal
disease ($140,862 per death) and West Nile Virus (WNV)
($293,960 per death).11,12 This high value, in comparison to
other infectious diseases, may be attributed to the age of fatal
cases in this review. The median age of death from RMSF in
these two communities is 14 years (range 1–78), whereas the
median age of fatal cases in WNV study was 76 years, and
more than 80% of deaths relating to pneumococcal disease
were among adults 65 years and older.11,12 This RMSF epi-
demic largely affects previously healthy children and young
adults who would otherwise have the most potential to con-
tribute economically to society.
Acute cost estimates provided in this study use all-inclusive
rates reimbursed by Medicaid, rather than itemized billing,
and do not represent the sum of actual expenses as direct bill-
ing information was not available. All-inclusive rates are not
specific to the treatment of RMSF, and generally represent
the minimum costs. Furthermore, expensive treatments, such
as extracorporeal membrane oxygenation (ECMO), which
cost upward of $16,000 for every 24 hours, were used to treat
patients in our cohort but were not accounted for in all-inclusive
rates.13 As the chart review was cross-sectional in nature,
long-term costs, such as rehabilitation and ambulatory care,
as well as loss of productivity due to disability, were not
included and could significantly increase the estimated costs
of disease. These calculations likely represent a gross under-
estimation of the costs sustained, but are valuable in that they
TABLE 1
Selected characteristics of RMSF case population in Arizona, 2002–2011
Characteristic Proportion of cases reporting
Male gender 106/205 (52%)
Median age (range) 11 years (7 months–78 years)
History of tick exposure 73/132 (55%)
Select severe sequelae




Renal insufficiency 17/203 (8%)
Multisystem organ failure 14/204 (7%)
Acute respiratory distress syndrome 13/204 (6%)
Coma 11/203 (5%)
Digital necrosis 3/201 (2%)
Events at discharge
Long-term sequelae 5/187 (3%)
Rehab facility 2/188 (1%)
Specialty follow-up 5/186 (3%)
Fatal outcome 15/205 (7%)
RMSF = Rocky Mountain spotted fever.
TABLE 2













ER visits 170 256 294 75,264
Outpatient
or clinic visits*
81 125 294 36,750
Inpatient days† 82 360 2,034 732,240
Transfers 48 48 1,500 72,000
ICU days 29 224 2,034 455,616
Bulk total
1,371,870
ER = emergency room; ICU = intensive care unit; IHS = Indian Health Service.
*Visit not resulting in an admission, excluding visits to ER.
†Excludes days spent in the ICU.
TABLE 3
Summary of direct and indirect costs associated with RMSF in
Arizona, 2002–2011
Point estimate Lower bound Upper bound
Direct costs
Acute medical costs $1,371,870 $1,371,870 $1,371,870
Long-term medical costs NA – –
Indirect costs





Lifetime lost due to death $11,631,998 $11,304,814 $11,959,182
Total $13,184,968 $12,852,638 $13,517,292
NA = not addressed in this study due to unavailability of relevant clinical information;
RMSF = Rocky Mountain spotted fever.
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underline the social and economic impact on affected com-
munities and emphasize the need for a more comprehensive
study to document the economic impact of this disease.
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